Abbott Laboratories (NYSE:ABT) Receives $140.79 Consensus PT from Brokerages

Abbott Laboratories (NYSE:ABT) has received a consensus recommendation of “Moderate Buy” from the twenty-two research firms that are covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation, seventeen have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $140.7895.

ABT has been the subject of a number of research analyst reports. Weiss Ratings reissued a “buy (b-)” rating on shares of Abbott Laboratories in a research report on Monday, December 29th. Mizuho increased their price objective on shares of Abbott Laboratories from $135.00 to $140.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 14th. Jefferies Financial Group raised their target price on shares of Abbott Laboratories from $145.00 to $149.00 and gave the company a “buy” rating in a research note on Thursday, October 16th. Oppenheimer decreased their price target on shares of Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a research report on Friday. Finally, Citigroup lowered their price target on Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating for the company in a report on Friday.

Hedge Funds Weigh In On Abbott Laboratories

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. IMG Wealth Management Inc. increased its position in shares of Abbott Laboratories by 759.1% in the 2nd quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock worth $26,000 after purchasing an additional 167 shares during the last quarter. Harbor Capital Advisors Inc. acquired a new position in Abbott Laboratories in the fourth quarter worth about $27,000. Cloud Capital Management LLC bought a new stake in Abbott Laboratories in the third quarter valued at about $29,000. Guerra Advisors Inc acquired a new stake in Abbott Laboratories during the third quarter valued at approximately $31,000. Finally, Anfield Capital Management LLC lifted its holdings in Abbott Laboratories by 81.3% during the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock worth $32,000 after buying an additional 104 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Trading Up 1.3%

Shares of ABT opened at $108.79 on Friday. Abbott Laboratories has a twelve month low of $105.78 and a twelve month high of $141.23. The firm has a market capitalization of $189.18 billion, a P/E ratio of 29.25, a price-to-earnings-growth ratio of 1.78 and a beta of 0.72. The company has a current ratio of 1.70, a quick ratio of 1.24 and a debt-to-equity ratio of 0.23. The stock’s fifty day simple moving average is $124.34 and its 200 day simple moving average is $128.12.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting the consensus estimate of $1.50. The company had revenue of $11.46 billion during the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a return on equity of 17.94% and a net margin of 14.72%.The firm’s revenue was up 4.4% on a year-over-year basis. During the same period in the prior year, the firm posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, equities research analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Thursday, January 15th will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.59. The ex-dividend date is Thursday, January 15th. Abbott Laboratories’s payout ratio is 67.74%.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott’s chairman, Robert B. Ford, bought $2 million of ABT stock — an insider buy that signals management confidence. Chairman Buys $2M in ABT
• Positive Sentiment: Evercore ISI reiterated an Outperform rating and said Abbott’s core growth drivers remain intact despite trimming its price target to $138 — supportive analyst view even after the quarter. Evercore: Core Growth Drivers Intact
• Positive Sentiment: Market momentum: Abbott snapped six straight sessions of losses, which can attract short‑covering and momentum buyers. ABT Snaps Losing Streak
• Positive Sentiment: Bullish analysis: At least one analyst piece highlights double‑digit earnings growth potential, reinforcing longer‑term upside narratives. Double‑Digit Earnings Growth Thesis
• Neutral Sentiment: Stock is a trending/searched ticker on retail platforms, drawing attention from momentum traders and retail buyers. Zacks: Trending Stock
• Neutral Sentiment: Commentary pieces ask whether January’s pullback is a buying opportunity, keeping ABT in retail and advisor conversations. Is the Pullback a Buy?
• Neutral Sentiment: Roundups of hedge‑fund and insider activity mention ABT among other names — informational but not clearly directional. Hedge Fund & Insider News
• Negative Sentiment: Multiple sell‑side firms trimmed price targets or issued cautious/pessimistic forecasts after the quarter (reduced revenue vs. expectations and cautious guidance). Notable items include cuts/negative notes from Royal Bank of Canada, Citigroup, Goldman Sachs, Sanford C. Bernstein and others — a headwind for near‑term sentiment. RBC Lowers PT to $135 Citigroup Pessimistic Forecast Goldman Sachs Negative Note

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.